Skip to main content
Premium Trial:

Request an Annual Quote

Axon and Affymetrix to Co-Develop Next-Generation GeneChip Scanner

NEW YORK, March 19 - Just two months after Affymetrix rolled out its own GeneChip 3000 scanner, Axon instruments announced that the two companies will be co-developing a scanner that will handle future versions of Affymetrix GeneChip-brand microarrays.


Axon, of Union City, Calif.and Melbourne, Australia, will modify its ImageExpress high-throughput cellular screening system - a high-end instrument - for screening of the arrays, the company said. 


The instrument will be designed to scan arrays that are formatted in microwell plates, which Affymetrix said recently it was developing for large-scale testing and diagnostic applications. (See BioArray News article.)


Axon also said it has already delivered three customized ImageExpress instruments to Affymetrix, but did not disclose the financial terms of the agreement.


Affymetrix launched its own GeneChip 3000 instrument in January, just as an earlier agreement with competitor Agilent technologies, under which Agilent produced a scanner for Affymetrix, was set to expire.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.